Use of drotrecogin alfa in necrotizing fasciitis: A case report and pharmacologic review

Journal of Intensive Care Medicine

Volumn 23, Issue 5, 2008, Pages 342-346

  Bland, Christopher M ^a   Frizzi, James D ^a   Reyes, Angel ^a  

^a EISENHOWER ARMY MEDICAL CENTER   (United States)

Author keywords

Drotrecogin alfa; Necrotizing fasciitis; Streptococcal pharyngitis

Indexed keywords

AMIODARONE; CLINDAMYCIN; DROTRECOGIN; HEMOGLOBIN; IMMUNOGLOBULIN G; NORADRENALIN; PENICILLIN G; VASOPRESSIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ASPIRATION; BLEEDING; BLOOD CULTURE; BLOOD TRANSFUSION; CASE REPORT; DEBRIDEMENT; DISEASE COURSE; DISEASE EXACERBATION; ERYTHROCYTE TRANSFUSION; FEVER; FLUID RESUSCITATION; HEART ATRIUM FIBRILLATION; HEMATOMA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; IMMUNOCOMPETENCE; INTENSIVE CARE UNIT; INTUBATION; LUNG EDEMA; MALE; NECROTIZING FASCIITIS; ODYNOPHAGIA; PARTIAL THROMBOPLASTIN TIME; PHYSICAL EXAMINATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTHROMBIN TIME; QUADRICEPS FEMORIS MUSCLE; SEPSIS; SOFT TISSUE DEFECT; SPLIT THICKNESS SKIN GRAFT; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SUPERINFECTION; TACHYCARDIA; TENDON RUPTURE; TREATMENT OUTCOME; WOUND DRESSING;

ADULT; ANTI-INFECTIVE AGENTS; DEBRIDEMENT; FASCIITIS, NECROTIZING; HUMANS; MALE; PROTEIN C; RECOMBINANT PROTEINS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 51849122157     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066608320908     Document Type: Article

References (18)

1. Lewis R. Soft tissue infections. In: Meakins J, ed. Surgical Infections. New York, NY: Scientific American, Inc.; 1994: 269-284.
2. Wong CH, Wang YS The diagnosis of necrotizing fasciitis. Curr Opin Infect Dis. 2005 ; 18: 101-106.
3. Stevens DL, Yan S., Bryant AE Penicillin-protein binding expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis. 1993 ; 167: 1401-1405.
4. Stevens DL, Bryant AE, Yan, S. Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents. 1994 ; 4: 297-301.
5. Leitch HA, Palepu A., Fernandes CM Necrotizing fasciitis secondary to group A streptococcus. Can Fam Physician. 2000 ; 46: 1460-1466.
6. Schrage B., Duan G., Yang LP, Fraser JD, Proft T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal super-antigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis. 2006 ; 43: 743-746.
7. Kaul R., McGeer A., Norrby-Teglund A., et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. Canadian Streptococcal Study Group. Clin Infect Dis. 1999 ; 28: 800-807.
8. Riseman JA, Zamboni WA, Curtis A., Graham DR, Konrad HR, Ross DS Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery. 1990 ; 108: 847-850.
9. Brown DR, Davis NL, Lepawsky M., et al. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg. 1994 ; 167: 485-489.
10. Martin GS, Mannino DM, Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 ; 348: 1546-1554.
11. Russell JA Management of sepsis. N Engl J Med. 2006 ; 355: 1699-1713.
12. Bernard GR, Vincent J-L., Laterre PF Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 ; 344: 699-709.
13. Abraham E., Laterre PF, Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005 ; 353: 1332-1341.
14. Nadel S., Goldstein B., Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multi-centre phase III randomized controlled trial. Lancet. 2007 ; 369: 836-843.
15. Vincent JL, Bernard GR, Beale R., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. 2005 ; 33: 2266-2277.
16. Purnell D., Hazlett T., Alexander S. A new weapon against severe sepsis related to necrotizing fasciitis. Dimens Crit Care Nurs. 2004 ; 26: 18-23.
17. Evaluate impact to protein C levels with changing dose/duration of drotrecogin alfa (activated) administered to severe sepsis patients. ClinicalTrials.gov Identifier NCT00386425, sponsor: Eli Lilly and Company.
18. Anaya DA, Dellinger EP Necrotizing soft tissue infection: diagnosis and management. Clin Infect Dis. 2007 ; 44: 705-710.